

Amendments to the claims

Please amend the claims as follows:

1. (Original) A process for the preparation of a spray-dried composition, the composition comprising i) talnetant particles having a D_{V90} in the range from 0.1 to 2.0 μm , ii) one or more ionic surfactant and iii) one or more soluble carrier, the process comprising a) wet milling a dispersion of the solid talnetant particles until the D_{V90} is in the range from 0.1 to 2.0 μm , which dispersion comprises the one or more ionic surfactant and the one or more soluble carrier, then b) spray drying or spray granulating the resulting dispersion.
2. (Original) A process according to claim 1 wherein the dispersion is wet-milled in a water-based medium.
3. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the dispersion contains 5 to 50 % w/w of talnetant.
4. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the dispersion contains 15 to 30 % w/w of talnetant.
5. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the ionic surfactant is an anionic surfactant.
6. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the ionic surfactant is sodium lauryl sulfate or dioctyl sodium sulfosuccinate.
7. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the ionic surfactant is sodium lauryl sulfate.
8. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the concentration of surfactant in the spray dried composition is 0.5 to 3.0% by weight of talnetant.

9. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the concentration of surfactant in the dispersion prior to spray drying is 0.05 to 5.0% by weight of dispersion.
10. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the dispersion contains 0.001 to 0.1 moles of ionic surfactant per mole of talnetant.
11. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the one or more soluble carrier is a soluble sugar.
12. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the one or more soluble carrier is selected from the group consisting of mannitol, sorbitol, lactose, lactitol, xylitol, trehalose, dextrose, sucrose, maltose, fructose, maltitol, xylitol, erythritol, polydextrose, isomalt, cyclodextrin and starch.
13. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the spray dried composition comprises one or more soluble carrier selected from the group consisting of mannitol, lactose, erythritol, polydextrose, isomalt and lactitol.
14. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the concentration of the one or more soluble carrier in the spray dried composition is 10 to 75 % by weight of talnetant.
15. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the concentration of the one or more soluble carrier in the dispersion prior to wet milling or after wet milling is 0.1 to 30% by weight of dispersion.
16. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the spray-dried composition comprises one or more anti-agglomeration agents.

17. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant.
18. (Currently Amended) A process according to ~~any preceding claim~~ claim 1 wherein the concentration of anti-agglomeration agent in the dispersion prior to spray drying is 0.1 to 10.0% by weight of dispersion.
19. (Original) A spray dried pharmaceutical composition comprising i) talnetant particles having a D_{v90} in the range from 0.1 to 2.0 μm , ii) one or more ionic surfactant and iii) one or more soluble carrier.
20. (Original) A pharmaceutical composition according to claim 19 wherein the ionic surfactant is an anionic surfactant.
21. (Currently Amended) A pharmaceutical composition according to claim 19 (~~or 20~~) wherein the ionic surfactant is sodium lauryl sulfate or dioctyl sodium sulfosuccinate.
22. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 21~~ claim 19 wherein the ionic surfactant is sodium lauryl sulfate.
23. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 22~~ claim 19 wherein the concentration of surfactant in the spray dried composition is 0.5 to 3.0% by weight of talnetant.
24. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 23~~ claim 19 wherein the one or more soluble carrier is a soluble sugar.
25. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 24~~ claim 19 wherein the one or more soluble carrier is selected from the group consisting of mannitol, sorbitol, lactose, lactitol, xylitol, trehalose, dextrose, sucrose, maltose, fructose, maltitol, xylitol, erythritol, polydextrose, isomalt, cyclodextrin and starch.

26. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 25~~ claim 19 wherein the spray dried composition comprises one or more soluble carrier selected from the group consisting of mannitol, lactose, erythritol, polydextrose, isomalt and lactitol.
27. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 26~~ claim 19 wherein the concentration of the one or more soluble carrier in the spray dried composition is 10 to 75 % by weight of talnetant.
28. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 27~~ claim 19 wherein the spray-dried composition comprises one or more anti-agglomeration agents.
29. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 19 to 28~~ claim 19 wherein the concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant.
30. (Currently Amended) A dosage form comprising a composition defined in ~~any one of claims 19 to 29~~ claim 19.
31. (Original) A dosage form according to claim 30 administered orally.
32. (Original) A dosage form according to claim 31 administered as a tablet.